Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: An open-label control study in chinese patients

Singapore Medical Journal

Volumn 53, Issue 4, 2012, Pages 273-276

  Wang, Zhenhua ^a,b   Wu, Shuming ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Doxycycline; Helicobacter pylori; Quadruple therapy; Rescue therapy

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; DOXYCYCLINE; ESOMEPRAZOLE; METRONIDAZOLE; TETRACYCLINE;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTICLE; CHINA; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPEN STUDY; UREA BREATH TEST;

ADOLESCENT; ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BREATH TESTS; DOXYCYCLINE; DRUG THERAPY, COMBINATION; ESOMEPRAZOLE SODIUM; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; TETRACYCLINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84859783562     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347:1175-86.
2. Fuccio L, Zagari RM, Eusebi LH, et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 2009; 151:121-8.
3. Talley NJ, Fock KM, Moayyedi P. Gastric Cancer Consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. Am J Gastroenterol 2008; 103:510-4.
4. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56:772-81.
5. Chey WD, Wong BC, Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102:1808-25.
6. Huang AH, Sheu BS, Yang HB, et al. Impact of Helicobacter pylori antimicrobial resistance on the outcome of 1-week lansoprazole-based triple therapy. J Formos Med Assoc 2000; 99:704-9.
7. Zanten SJ, Bradette M, Farley A, et al. The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment Pharmacol Ther 1999; 13:289-95.
8. Sheu BS, Wu JJ, Lo CY, et al. Impact of supplement with Lactobacillusand Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002; 16:1669-75.
9. Bazzoli F, Pozzato P, Rokkas T. Helicobacter pylori: the challenge in therapy. Helicobacter 2002; 7 suppl 1:43-9.
10. Georgopoulos SD, Ladas SD, Karatapanis S, et al. Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. Aliment Pharmacol Ther 2002; 16:569-75.
11. Peitz U, Sulliga M, Wolle K, et al. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther 2002; 16:315-24.
12. Agudo S, Alarcón T, Cibrelus L, et al. High percentage of clarithromycin and metronidazole resistance in Helicobacter pylori clinical isolates obtained from Spanish children. Rev Esp Quimioter 2009; 22:88-92.
13. O'connor A, Taneike I, Nami A, et al. Helicobacter pylori resistance to metronidazole and clarithromycin in Ireland. Eur J Gastroenterol Hepatol 2010; 22:1123-7.
14. Chang WL, Sheu BS, Cheng HC, et al. Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. J Gastroenterol Hepatol 2009; 24:1230-5.
15. Mégraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 17:1333-43.
16. Gisbert JP, Pajares JM. Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002; 16:1047-57.
17. Wong WM, Gu Q, Chu KM, et al. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006; 23:421-7.
18. Chinese Helicobacter pylori Research Group, Chinese Society of Gastroenterology. Prevalence of Helicobacter pylori resistance to antibiotics and its influence on the treatment outcome in China: A multicenter clinical study. Weichang Bingxue 2007; 12:525-30.
19. Barza M, Schiefe RT. Antimicrobial spectrum, pharmacology and therapeutic use of antibiotics. Part 1: tetracyclines. Am J Hosp Pharm 1977; 34:49-57.
20. Casado MJ. Doxycycline in respiratory tract infections. Report of a retrospective study in Spain during the winter 1972-1973. Chemotherapy 1975; 21 (Suppl 1):76-90.
21. Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther 2005; 27:1329-42.
22. Taghavi SA, Jafari A, Eshraghian A. Efficacy of a new therapeutic regimen versus two routinely prescribed treatments for eradication of Helicobacter pylori: a randomized, double-blind study of doxycycline, co-amoxiclav, and omeprazole in Iranian patients. Dig Dis Sci 2009; 54:599-603.
23. Cammarota G, Martino A, Pirozzi G, et al. High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a cultureguided, third-line treatment approach for Helicobacter pylori infection. Aliment Pharmacol Ther 2004; 19:789-95.